Description
The medicine Bosutinib is a kinase inhibitor recommended for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy and Chronic phase, accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to initial therapy.
Dosage:Bosutinib tablets come in 100 mg, 400 mg, and 500 mg to administer orally via the mouth. The recommended dose and schedule of Bosutinib is 500 mg orally once daily with food. Continue treatment with Bosutinib until disease progression or patient intolerance. If a dose is missed beyond 12 hours, the patient should skip the dose and take the usually prescribed amount the following day.
Side Effects:The most common side effects of Bosutinib are:
- Diarrhea
- Nausea
- Thrombocytopenia
- Vomiting
- abdominal pain
- Rash
- Anemia
- Pyrexia
- Fatigue
There are reports of gastrointestinal toxicity such as diarrhea, nausea, vomiting, and abdominal pain in patients receiving the medicine Bosutinib. One should monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and fluid replacement. To manage gastrointestinal toxicity, withhold, dose reduce, or discontinue Bosutinib as necessary.
Thrombocytopenia, anemia, and neutropenia occur with treatment with Bosutinib. Patients with CML who are receiving Bosutinib tablets should have a complete blood count performed weekly for the first month and then monthly thereafter, or as clinically indicated. To manage myelosuppression, withhold, dose reduce, or discontinue the medicine as necessary.
Cases of Hepatic toxicity are reported recently in patients administered Bosutinib 100 mg, 400 mg, and 500 mg. One should perform monthly hepatic enzyme tests for the first three months of treatment with Bosutinib and as clinically indicated. In patients with transaminase elevations, monitor liver enzymes more frequently. Withhold, dose reduce, or discontinue Bosutinib as needed.
The medicine Bosutinib can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should be advised to avoid pregnancy while being treated with Bosutinib. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
